These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21803095)

  • 1. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
    Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
    Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
    Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
    Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated
    Xv Z; Lv J; Jiang J; Wang W; Feng F; Zhang L; Xue X; Li W
    Viral Immunol; 2019 Sep; 32(7):308-317. PubMed ID: 31381497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris.
    Jiang Z; Tong G; Cai B; Xu Y; Lou J
    Protein Expr Purif; 2011 Dec; 80(2):203-10. PubMed ID: 21821128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.
    Liu HB; Chaturvedi PK; Battogtokh G; Bang HJ; Kim IW; Kim YW; Park KS; Ahn WS
    Mol Biotechnol; 2013 Jun; 54(2):361-70. PubMed ID: 22669586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles.
    Gupta G; Glueck R; Rishi N
    Biologicals; 2017 Mar; 46():11-22. PubMed ID: 28012703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
    Zhang T; Chen X; Liao G; Hu M; Xu J; Xu X
    J Med Virol; 2020 Dec; 92(12):3750-3758. PubMed ID: 31994744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.